Janus kinase (JAK) inhibitors look to be a good treatment option for the newly recognized, rare autoimmune disease known as ...

The following is a summary of “Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis,” published in the February 2025 ...

For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus stan ...

The following is a summary of “Tacrolimus as first line therapy in a U.S. cohort of idiopathic inflammatory myopathies ...

Adding obinutuzumab to standard therapy for active lupus nephritis led to significantly higher rates of complete renal ...

The addition of itacitinib to standard graft-versus-host-disease prophylaxis may reduce severe toxicities following ...

Dermatologists are practicing in an “era of good efficacy” of nonsteroidal topical therapies for psoriasis, and they can help patients access newer topical medications by working with pharmacies that ...

Net interest income was 14% higher YoY, at ₹587.7 crore, due to steady loan growth & higher interest margins than Q3 FY24 levels of ₹516 crore.

A new study published in the journal of Dermatologic Therapy found that the addition of 1 mg/day minoxidil to the ...

In the United States, SLE treatment trends between 2007 and 2023 show a continued reliance on glucocorticoids, despite advances in steroid-sparing agents.